Drospifem 20 (ethinylestradiol, drospirenone) coated tablets 0.02 mg/3 mg. №28


Manufacturer: Germany

Oral contraception. The decision to prescribe Drospifem 20 should be made taking into account the individual risk factors of the patient, in particular the risk factors for venous thromboembolism (VTE). You should also compare the risk of VTE during the treatment of Drospifem 20 with such a risk during treatment with other combined hormonal contraceptives (KGC) (see the sections “Contraindications” and “Features of use”).



Drospifem 20 Composition
Active ingredients: ethinylestradiol, drospirenone;

1 active pink tablet contains 0.02 mg ethinylestradiol and 3 mg drospirenone;

1 white placebo tablet does not contain active substances;

Drospifem 20 Excipients:

1 active tablet contains lactose, corn starch, maltodextrin, magnesium stearate, Opadry 10A240000 pink (hypromellose, talc, titanium dioxide (E 171), polysorbate 80, iron oxide red (E172)).

1 placebo tablet contains lactose, corn starch, maltodextrin, magnesium stearate, white mixture for film coating (hypromellose, lactose, titanium dioxide (E 171), macrogol 4000, sodium)).

Drospifem 20 Contraindications
The presence or risk of developing venous thromboembolism (VTE).
The presence or risk of developing arterial thromboembolism (ATE).
A history of severe liver disease or a history of severe liver disease before liver function tests return to normal.
Severe renal failure or acute renal failure.
Current or history of liver tumors (benign or malignant). Or suspected malignant tumors (for example, of the genitals or mammary glands), dependent on sex hormones.
Vaginal bleeding of unknown etiology.
Concomitant use with medicines containing ombitasvir / paritaprevir / ritonavir and dazabuvir.
Hypersensitivity to active ingredients or to any of the components of the drug.
Mode of application
The tablets should be taken at about the same time every day, with a small amount of liquid if necessary, in the sequence indicated on the blister pack. Take 1 tablet daily for 28 consecutive days. Taking pills from each next package should begin the next day after the end of the previous package. Menstrual bleeding usually occurs 2-3 days after you start taking the placebo pills and does not necessarily end before you start taking the pills from the new package.

Application features
The use is contraindicated.

The drug Drospifem 20 is indicated for use as directed by a doctor only after the onset of persistent menstruation.

Does not affect.

There is still no evidence of an overdose of the drug Drospifem 20. As the general experience with COCs shows, overdose may cause nausea, vomiting and withdrawal bleeding. Withdrawal bleeding can be observed in girls even before the onset of menarche in case of unintentional / accidental use of the drug. There is no specific antidote; treatment must be symptomatic.